Labcorp Holdings Inc.

Company facts

Industry

Services-Medical Laboratories

Headquarters

Burlington, North Carolina

Most recent report

8-K, filed Aug 28, 2026

Filings on record

1,001+ filings

On EDGAR

CIK 920148

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 3 of 13 sections worth reading, with 3 positive, 10 notable, and 1 negative flags.

• Financial Statements (Item 1)

  Core financial results, litigation updates, and capital allocation actions require review.
  Positive

  • Board authorized additional $1,000.0 in share repurchases on July 8, 2026.
  • Texas Supreme Court reversed appeals court, reinstated summary judgment in company's favor on Texas Medicaid billing case.
  Notable

  • H1 2026 share repurchases $451.8M, more than double H1 2025's $200.0M.
  • Entered into a settlement agreement with the DOJ for urine drug testing on July 15, 2026 (post-period).
  Negative

  • Patent infringement verdict: $272M jury award plus $100M enhanced damages; appeal pending with bond posted.

• Management's Discussion (Item 2)

  Full of period results: revenue, margins, cash, debt, buyback, and an acquisition.
  Positive

  • Q2 2026 revenue up 5.8% to $3,731.1M, with organic growth of 4.2%. Both segments grew.
  Notable

  • OBBBA enacted July 2025 may reduce testing utilization; company says no material impact expected.
  • Cash and equivalents fell to $141.8M from $981.1M at March 31, 2026, largely from investing and buybacks.
  • New $750M term loan (March 2026, matures 2028) used to redeem 1.55% senior notes; floating SOFR+0.700%.
  • Board authorized $1.0B additional share repurchases on July 8, 2026, bringing total to $1,378.6M available.
  • Noncancelable supply contract obligates $115.4M through 2028; $20.9 due remainder 2026, $74.0 in 2028.
  • Agreed to acquire select assets of an outreach lab business for ~$155M, closing expected in Q3 2026.

• Market Risk (Item 3)

  Contains quantified FX translation swing and increased debt exposure.
  Notable

  • FX translation shifted from +$156.6M gain to -$39.1M loss in Q2 2026 vs Q2 2025, reducing equity.
  • AR Facility variable-rate debt increased to $550M at June 30 2026 from $525M at March 31 2026.

What changed: Jun 2026 vs. Mar 2026

About 13% of LH's Jun 2026 10-Q is new information. 39 paragraphs were added, 110 changed, and 28 removed. Below are the most important lines SECSift identified.

• Item 2 55
• Item 1 42
• Item 3 5
• Item 4 2
• Item 5 2
• Part II 1
• Item 6 1